DUTASTERIDE AS AN EFFECTIVE TREATMENT IN ANDROGENETIC ALOPECIA – A LITERATURE REVIEW
Abstract
Introduction: Androgenetic alopecia (AGA) is a common hereditary condition characterized by progressive hair loss in both men and women. While not a direct health threat, AGA significantly affects psychological well-being due to the role of hair in self-image and perceived attractiveness. Dutasteride, initially approved for benign prostatic hyperplasia, has demonstrated greater efficacy than finasteride in treating AGA. Its use in mesotherapy may help reduce systemic side effects, although more research is needed to confirm safety and define optimal treatment protocols.
Aim of study: To review current evidence on the efficacy and safety of dutasteride in the treatment of AGA and assess its potential as a therapeutic option.
Methods and material: A literature search was conducted using PubMed and Scopus to identify relevant studies on the use of dutasteride in AGA.
Results: Dutasteride 0.5 mg has shown superior efficacy compared to finasteride 1 mg and placebo in increasing hair count and shaft thickness in men with AGA. As a dual 5α-reductase inhibitor, dutasteride offers broader inhibition than finasteride, which targets only the type 2 isoenzyme. Higher doses, such as 2.5 mg, may yield even greater improvements. Mesotherapy with dutasteride appears to be well tolerated and may reduce systemic exposure, though evidence remains limited, and further studies are required to determine long-term safety and appropriate dosing.
Conclusion: Although not officially approved for AGA, dutasteride demonstrates superior clinical efficacy compared to finasteride. Side effects, particularly regarding sexual function, appear similar; however, concerns about long-term risks such as depression and metabolic changes persist. These should be carefully considered in patient consultations. Mesotherapy may offer a safer delivery method, but more robust data are needed to support its widespread use.
References
Lolli, F., Pallotti, F., Rossi, A., Fortuna, M. C., Caro, G., Lenzi, A., Sansone, A., & Lombardo, F. (2017). Androgenetic alopecia: A review. Endocrine, 57(1), 9–17. https://doi.org/10.1007/s12020-017-1280-y
Bajoria, P. S., Dave, P. A., Rohit, R. K., Tibrewal, C., Modi, N. S., Gandhi, S. K., & Patel, P. (2023). Comparing current therapeutic modalities of androgenic alopecia: A literature review of clinical trials. Cureus, 15(7), e42768. https://doi.org/10.7759/cureus.42768
Ellis, J. A., & Harrap, S. B. (2001). The genetics of androgenetic alopecia. Clinical Dermatology, 19(2), 149–154. https://doi.org/10.1016/s0738-081x(00)00125-5
Mahé, Y. F., Michelet, J. F., Billoni, N., Jarrousse, F., Buan, B., Commo, S., Saint-Léger, D., & Bernard, B. A. (2000). Androgenetic alopecia and microinflammation. International Journal of Dermatology, 39(8), 576–584. https://doi.org/10.1046/j.1365-4362.2000.00612.x
Chanprapaph, K., Sutharaphan, T., & Suchonwanit, P. (2021). Scalp biophysical characteristics in males with androgenetic alopecia: A comparative study with healthy controls. Clinical Interventions in Aging, 16, 781–787. https://doi.org/10.2147/CIA.S31017
Sadick, N., & Arruda, S. (2021). Understanding causes of hair loss in women. Dermatologic Clinics, 39(3), 371–374. https://doi.org/10.1016/j.det.2021.03.002
Gupta, A. K., Bamimore, M. A., & Foley, K. A. (2022). Efficacy of non-surgical treatments for androgenetic alopecia in men and women: A systematic review with network meta-analyses, and an assessment of evidence quality. Journal of Dermatological Treatment, 33(1), 62–72. https://doi.org/10.1080/09546634.2020.1749547
Varothai, S., & Bergfeld, W. F. (2014). Androgenetic alopecia: An evidence-based treatment update. American Journal of Clinical Dermatology, 15(3), 217–230. https://doi.org/10.1007/s40257-014-0077-5
Koch, S. L., Tridico, S. R., Bernard, B. A., Shriver, M. D., & Jablonski, N. G. (2020). The biology of human hair: A multidisciplinary review. American Journal of Human Biology, 32(2), e23316. https://doi.org/10.1002/ajhb.23316
Keam, S. J., & Scott, L. J. (2008). Dutasteride. Drugs, 68, 463–485. https://doi.org/10.2165/00003495-200868040-00008
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., Andriole, G., & ARIA3001, ARIA3002, and ARIA3003 Study Investigators. (2002). Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology, 60(3), 434–441. https://doi.org/10.1016/s0090-4295(02)01905-2
Azzouni, F., Godoy, A., Li, Y., & Mohler, J. (2012). The 5 alpha-reductase isozyme family: A review of basic biology and their role in human diseases. Advances in Urology, 2012, 530121. https://doi.org/10.1155/2012/530121
Herz-Ruelas, M. E., Álvarez-Villalobos, N. A., Millán-Alanís, J. M., de León-Gutiérrez, H., Ocampo-Garza, S. S., Gómez-Flores, M., & Grimalt, R. (2020). Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: A systematic review. Skin Appendage Disorders, 6(6), 338–345. https://doi.org/10.1159/000510697
Swerdloff, R. S., Dudley, R. E., Page, S. T., Wang, C., & Salameh, W. A. (2017). Dihydrotestosterone: Biochemistry, physiology, and clinical implications of elevated blood levels. Endocrine Reviews, 38(3), 220–254. https://doi.org/10.1210/er.2016-1067
Jimenez, F., Alam, M., Vogel, J. E., & Avram, M. (2021). Hair transplantation: Basic overview. Journal of the American Academy of Dermatology, 85(4), 803–814. https://doi.org/10.1016/j.jaad.2021.03.12
Rossi, A., Cantisani, C., Melis, L., Iorio, A., Scali, E., & Calvieri, S. (2012). Minoxidil use in dermatology, side effects and recent patents. Recent Patents on Inflammation & Allergy Drug Discovery, 6(2), 130–136. https://doi.org/10.2174/187221312800166859
Nemane, S. T., Bhusnure, O. G., Gholve, S. B., Mitakari, P. R., & Karwa, P. N. (2019). A review on finasteride: A 5-alpha reductase inhibitors, its mechanism, facts and benefits. Journal of Drug Delivery and Therapeutics, 9(3-s), 1132–1136. https://doi.org/10.22270/jddt.v9i3-s.3013
Courtney, A., Triwongwarant, D., Chim, I., Eisman, S., & Sinclair, R. (2023). Evaluating 5 alpha reductase inhibitors for the treatment of male androgenic alopecia. Expert Opinion on Pharmacotherapy, 24(18), 1919–1922. https://doi.org/10.1080/14656566.2023.2280630
Escamilla-Cruz, M., Magaña, M., Escandón-Perez, S., & Bello-Chavolla, O. Y. (2023). Use of 5-alpha reductase inhibitors in dermatology: A narrative review. Dermatology and Therapy, 13(8), 1721–1731. https://doi.org/10.1007/s13555-023-00974-4
Eun, H. C., Kwon, O. S., Yeon, J. H., Shin, H. S., Kim, B. Y., Ro, B. I., Cho, H. K., Sim, W. Y., Lew, B. L., Lee, W. S., Park, H. Y., Hong, S. P., & Ji, J. H. (2010). Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study. Journal of the American Academy of Dermatology, 63(2), 252–258. https://doi.org/10.1016/j.jaad.2009.09.018
Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., & Rittmaster, R. S. (2006). The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 55(6), 1014–1023. https://doi.org/10.1016/j.jaad.2006.05.007
Gubelin Harcha, W., Barboza Martínez, J., Tsai, T. F., Katsuoka, K., Kawashima, M., Tsuboi, R., Barnes, A., Ferron-Brady, G., & Chetty, D. (2014). A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. Journal of the American Academy of Dermatology, 70(3), 489–498.e3. https://doi.org/10.1016/j.jaad.2013.10.049
Rowland, D. L., Motofei, I. G., Păunică, I., Banu, P., Nistor, M. F., Păunică, S., & Constantin, V. D. (2018). Androgenic alopecia—The risk–benefit ratio of finasteride. Journal of Mind and Medical Sciences, 5(1), 1–6. https://doi.org/10.22543/7674.51.P16
Zhou, Z., Song, S., Gao, Z., Wu, J., Ma, J., & Cui, Y. (2019). The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: A systematic review and meta-analysis. Clinical Interventions in Aging, 14, 399–406. https://doi.org/10.2147/CIA.S192435
Stough, D. (2007). Dutasteride improves male pattern hair loss in a randomized study in identical twins. Journal of Cosmetic Dermatology, 6(1), 9–13. https://doi.org/10.1111/j.1473-2165.2007.00297.x
Olszewska, M., & Rudnicka, L. (2005). Effective treatment of female androgenic alopecia with dutasteride. Journal of Drugs in Dermatology, 4(5), 637–640. PMID: 16167423
Deng, T., Duan, X., He, Z., Zhao, Z., & Zeng, G. (2020). Association between 5-alpha reductase inhibitor use and the risk of depression: A meta-analysis. Urology Journal, 18(2), 144–150. https://doi.org/10.22037/uj.v16i7.5866
Traish, A. M. (2020). Health risks associated with long-term finasteride and dutasteride use: It's time to sound the alarm. World Journal of Men's Health, 38(3), 323–337. https://doi.org/10.5534/wjmh.200012
Rogers, N. E., & Avram, M. R. (2008). Medical treatments for male and female pattern hair loss. Journal of the American Academy of Dermatology, 59(4), 547–566. https://doi.org/10.1016/j.jaad.2008.07.001
Sivagnanam, G. (2010). Mesotherapy – The French connection. Journal of Pharmacology & Pharmacotherapeutics, 1(1), 4–8. https://doi.org/10.4103/0976-500X.64529
Sobhy, N., Aly, H., El Shafee, A., & El Deeb, M. (2013). Evaluation of the effect of injection of dutasteride as mesotherapeutic tool in treatment of androgenetic alopecia in males. Our Dermatology Online, 4(1), 40–45. https://doi.org/10.7241/ourd.20131.08
Abdallah, M. A., El-Zawahry, K. A., & Besar, H. (2009). Mesotherapy using dutasteride-containing solution in male pattern hair loss: A controlled pilot study. Journal of the Pan Arab League of Dermatologists, 20, 137–145. https://doi.org/10.4103/ijt.ijt_73_16
Saceda-Corralo, D., Rodrigues-Barata, A. R., Vañó-Galván, S., & Jaén-Olasolo, P. (2017). Mesotherapy with dutasteride in the treatment of androgenetic alopecia. International Journal of Trichology, 9(3), 143–145. https://doi.org/10.4103/ijt.ijt_73_16
Views:
42
Downloads:
20
Copyright (c) 2025 Dawid Sewruk, Karol Kanon, Mathias Spitaleri, Wiktor Gąska, Oskar Sienkiel, Filip Kieloch, Agnieszka Fitas, Wojciech Gąska, Karolina Dębek-Kalinowska, Julia Głowacka
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
